We acknowledge that the cytotoxic effect of FKBP13 silencing was significant but not sufficient to deplete all plasmacytoma cells, perhaps due in part to the low efficiency of DNA delivery into plasmacytoma cells (usually 10–20%), which may lead to underestimating the effectiveness of FKBP13. The gene discussed is FKBP2; the disease is plasmacytoma.